Idris, O.A.; Westgate, D.; Saadaie Jahromi, B.; Shebrain, A.; Zhang, T.; Ashour, H.M.
PD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights. Biomedicines 2025, 13, 889.
https://doi.org/10.3390/biomedicines13040889
AMA Style
Idris OA, Westgate D, Saadaie Jahromi B, Shebrain A, Zhang T, Ashour HM.
PD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights. Biomedicines. 2025; 13(4):889.
https://doi.org/10.3390/biomedicines13040889
Chicago/Turabian Style
Idris, Omer A., Diana Westgate, Bahar Saadaie Jahromi, Abdulaziz Shebrain, Tiantian Zhang, and Hossam M. Ashour.
2025. "PD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights" Biomedicines 13, no. 4: 889.
https://doi.org/10.3390/biomedicines13040889
APA Style
Idris, O. A., Westgate, D., Saadaie Jahromi, B., Shebrain, A., Zhang, T., & Ashour, H. M.
(2025). PD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights. Biomedicines, 13(4), 889.
https://doi.org/10.3390/biomedicines13040889